Showing results (121-130 of 280) with videos related to
Sort By:
Pageof 28
Prostate Cancer and Prostatic Diseases|May 15, 2020
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancerNeal Shore, Celestia S Higano, Daniel J George, et al.Carcinogenesis|May 5, 2018
Single-nucleotide polymorphisms of stemness genes predicted to regulate RNA splicing, microRNA and oncogenic signaling are associated with prostate cancer survivalJennifer A Freedman, Yanru Wang, Xuechan Li, et al.The New England Journal of Medicine|February 17, 2012
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancerGiancarlo Agnelli, Daniel J George, Ajay K Kakkar, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancerWilliam K Oh, Elizabeth Hagmann, Judith Manola, et al.Oncology (Williston Park, N.Y.)|April 17, 2017
How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies?Ramiro Jose Madden-Fuentes, Bridget F Koontz, Michael R Harrison, et al.Cancer|October 6, 2020
Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)Ronald C Chen, Toni K Choueiri, Marion Feuilly, et al.Cancers|October 14, 2023
Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate CancerFred Saad, Daniel J George, Michael S Cookson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2015
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)Keith T Flaherty, Judith B Manola, Michael Pins, et al.Nature Communications|October 10, 2022
Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trialRobert J Motzer, Jean-François Martini, Xinmeng J Mu, et al.American Journal of Physiology. Renal Physiology|December 2, 2004
Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopyRachel Katz-Brull, Neil M Rofsky, Martina M Morrin, et al.Pageof 28